Keywords
Primary multiple myeloma
Clinical efficacy
Submitted : 2022-08-07
Accepted : 2022-08-22
Published : 2022-09-06
Abstract
Objective: To study the clinical efficacy of bortezomib combined with dexamethasone in the treatment of primary multiple myeloma. Methods: Seventy patients with primary multiple myeloma treated in Shaanxi Provincial People’s Hospital between January 2020 and January 2021 were divided into two groups, a control group and a study group, using the random number table method; 35 patients in the control group were treated with conventional treatment, and the other 35 patients in the study group were treated with bortezomib combined with dexamethasone. The patients’ clinical outcomes, clinical indices, satisfaction, and adverse reactions were compared between the two groups. Results: There were significant differences (p < 0.05) in the indices between the two groups of patients treated with different treatment modalities for primary multiple myeloma. Conclusion: The use of bortezomib combined with dexamethasone for patients with primary multiple myeloma can effectively improve the treatment outcomes, clinical indices, patient satisfaction, and adverse reactions; hence, it is worthy to be widely promoted in clinical practice.
References
Yu JS, Li FM, Situ XH, 2020, Study on the Nursing Response of Bortezomib Combined with Dexamethasone in the Treatment of Multiple Myeloma. Massage and Rehabilitation Medicine, 11(2): 66–67.
Yu W, 2020, Clinical Efficacy Analysis of Bortezomib Combined with Dexamethasone in the Treatment of Patients with Multiple Myeloma. Contemporary Medicine, 26(35): 149–151.
Lu J, Zhu XJ, 2020, Clinical Efficacy and Toxic Side Effects of Bortezomib Combined with Cyclophosphamide and Dexamethasone in the Treatment of Multiple Myeloma. Hebei Medicine, 26(4): 537–540.
Ding H, 2020, Clinical study on the Treatment of Phlegm-Stasis Paralysis Type Primary Multiple Myeloma with Huachansu Tablets Combined with TD Regimen, dissertation, Nanjing University of Traditional Chinese Medicine.
Wang Y, Lv G, Zhang Y, et al., 2020, Cost and Efficacy Analysis of Bortezomib, Dexamethasone and Thalidomide Regimen in the Treatment of Multiple Myeloma. Modern Medical Oncology, 28(4): 622–625.
Lv N, Wang H, Liu F, et al., 2020, Clinical Efficacy of Bortezomib Combined with Dexamethasone in the Treatment of Patients with Multiple Myeloma. International Journal of Medicine and Health, 26(1): 108–109.
Yang F, Qing S, Xu F, et al., 2020, Evaluation of the Efficacy and Safety of Bortezomib + Cyclophosphamide + Dexamethasone Weekly Regimen Versus Conventional Regimen in the Treatment of Primary Multiple Myeloma. Anhui Medicine, 24(11): 2295–2298.
Liu S, Liu Y, 2021, Clinical Efficacy of Melphalan Tablets in Combination with Bortezomib and Dexamethasone in the Treatment of Multiple Myeloma. Journal of Clinical Rational Drug Use, 14(24): 86–88.
Wang MJ, Yang LH, Yan QX, 2021, Efficacy of Bortezomib Combined with Cyclophosphamide and Dexamethasone in the Treatment of Multiple Myeloma and the Effects on Patients’ Renal Function Indicators and Adverse Effects. Hebei Medicine, 27(5): 864–869.
Huang Z, Yang C, Liang I, et al., 2022, Evaluation of the Efficacy of Recombinant Human Erythropoietin in Combination with Bortezomib and Dexamethasone in the Treatment of Multiple Myeloma in the Elderly. Chinese Contemporary Medicine, 29(1): 39–42 + 46.
Ge Y, Ding X, Gao L, 2020, Efficacy and Safety Analysis of Bortezomib Combined with Dexamethasone in the Treatment of Multiple Myeloma. Medical Theory and Practice, 33(1): 65–66.
Guo ZJ, Yang Q, 2020, Efficacy and Safety Analysis of Bortezomib Combined with Dexamethasone in the Treatment of Patients with Multiple Myeloma. Primary Care Forum, 24(22): 3147–3148.
Zhang G, 2020, Clinical Efficacy of Bortezomib Combined with Dexamethasone in the Treatment of Patients with Multiple Myeloma. China Health Care Nutrition, 30(8): 95.
Xiao J, 2020, Evaluation of the Efficacy of Cyclophosphamide Combined with Injectable Bortezomib and Dexamethasone in the Treatment of Multiple Myeloma. Northern Pharmacology, 17(7): 163–164.
Tang SL, Li J, 2021, An Investigation of the Efficacy of Bortezomib and Dexamethasone Combined with Hemodialysis in the Treatment of Multiple Myeloma Nephropathy. Contemporary Medicine Series, 19(18): 110–112.
Guo T, Ji D-M, 2020, Efficacy and Safety of Different Doses of Bortezomib Combined with Dexamethasone and Thalidomide in the Treatment of Multiple Myeloma. Health Care Medicine Research and Practice, 17(4): 42–46.
Mi HY, Yang QA, Sun YQ, 2021, Clinical Effects of Bortezomib Combined with Dexamethasone in the Treatment of Multiple Myeloma in the Elderly. Chinese Contemporary Medicine, 28(13): 12–16.
Huang G, Liao JJ, Huang JX, et al., 2020, Clinical Efficacy and Safety of Bortezomib + Cyclophosphamide + Dexamethasone in the Treatment of Multiple Myeloma. China Modern Drug Application, 14(10): 159–160.
Ma YQ, Yang XT, 2020, Effectiveness of Bortezomib in Combination with Adriamycin and Dexamethasone in the Treatment of Multiple Myeloma. Henan Medical Research, 29(21): 3932–3934.
Lei LH, He D, Lin J, et al., 2020, Effects of Bortezomib Combined with Dexamethasone on Bone Metabolism and Immune Function in Patients with Multiple Myeloma. Journal of Practical Cancer, 35(6): 917–920.
Shen M, Huang Z, Zhang J, et al., 2021, Clinical Observation on the Efficacy of Bortezomib Maintenance Therapy in 25 Patients with Non-Transplanted Multiple Myeloma. Chinese Journal of Experimental Hematology, 29(1): 131–136.